serena williams glp-1 ad Super Bowl LX Commercial ‘Healthier on Ro’ Serena Williams Joins Ro as

Pfizer has said it expects pills to eventually capture about a third of the obesity drug market, which is predicted to grow to about $130 billion by the end of the decade.

Learn about Noom's GLP-1 Companion in this informative video, offering insight and resources to help close the care gap for your GLP-1 population.

Learn why rotating your injection sites matters, how to do it safely, and how Shotsy makes it effortless to track.

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling compounded versions of its meds.

CONTRIBUTED BY REAL CHEMISTRY | BY RITA GLAZE-ROWE ALABAMA A new study on behalf of Real Chemistry has identified which state Medicaid programs cover GLP-1s.The growing popularity of GLP-1 receptor agonists including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly has added fuel to an already fiery []